QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Résumé Extracto Full Text PDF Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Articles Ahead of Print [Order Reprint] Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pai, M. P Articles by Koster, S. A Search for Related Content PubMed PubMed Citation Articles by Pai, M. P Articles by Koster, S. A

INFECTIOUS DISEASES

Epidemiology of Vancomycin-Induced Neutropenia in Patients Receiving Home Intravenous Infusion Therapy

Assistant Professor, College of Pharmacy, University of New Mexico, Albuquerque, NM

Renee-Claude Mercier, PharmD

Associate Professor, College of Pharmacy, University of New Mexico

Sarah A Koster, BA

Research Assistant, College of Pharmacy, University of New Mexico

Reprints: Dr. Pai, College of Pharmacy, MSC09 5360, 1 University of New Mexico, Albuquerque, NM 87131-0001, fax 505/272-6749, apai{at}salud.unm.edu

BACKGROUND: Vancomycin is frequently used to manage serious resistant gram-positive infections. Neutropenia, whose epidemiology has not been well characterized, is a potentially serious adverse event associated with the use of vancomycin.

OBJECTIVE: To characterize the incidence and risk factors for development of vancomycin-induced neutropenia in patients treated with home intravenous vancomycin therapy.

METHODS: A retrospective chart review was conducted of adult patients receiving vancomycin therapy through the University of New Mexico Home Intravenous Infusion Clinic between January 1998 and December 2004. Data collection included demographics, comorbid conditions, dose and duration of vancomycin therapy, indications for vancomycin use, vancomycin concentrations, all concurrent medications, laboratory data, culture and susceptibility data, reasons for antibiotic alteration or discontinuations, all other recorded adverse events, management of adverse events, and outcomes of adverse events.

RESULTS: A total of 372 charts of patients managed through the clinic were reviewed and 114 patients treated with vancomycin were identified. Fourteen (12%) cases of vancomycin-induced neutropenia were identified; 4 (3.5%) cases included a reduction in absolute neutrophil count to 500 cells/mm³ or less. The mean ± SD duration of vancomycin therapy and time to neutropenia were 32 ± 29 and 26 ± 15 days, respectively. Laboratory monitoring was performed on a weekly basis and resolution of vancomycin-induced neutropenia occurred promptly after discontinuation. Total vancomycin doses used and serum concentrations were not associated with the development of neutropenia.

CONCLUSIONS: Vancomycin-induced neutropenia may occur at a higher frequency than previously reported. Clinicians should monitor hematologic parameters at least weekly in patients receiving home intravenous vancomycin therapy.

Key Words: neutropenia, red man syndrome, vancomycin

Published Online, January 24, 2006. www.theannals.com, DOI 10.1345/aph.1G436

This article has been cited by other articles:

				C. B Whitman, J. M Joseph, and L. O Sjoholm Cephalosporin-Induced Leukopenia Following Rechallenge with Cefoxitin Ann. Pharmacother., September 1, 2008; 42(9): 1327 - 1332. [Abstract] [Full Text] [PDF]

				K. A Mergenhagen and M. T Pasko Daptomycin Use After Vancomycin-Induced Neutropenia in a Patient with Left-Sided Endocarditis Ann. Pharmacother., September 1, 2007; 41(9): 1531 - 1535. [Abstract] [Full Text] [PDF]

				S.-H. Hsiao, C.-M. Chang, J.-C. Tsai, C.-Y. Lin, L.-H. Liao, W.-L. Lin, and T.-J. Wu Glycopeptide-Induced Neutropenia: Cross-Reactivity Between Vancomycin and Teicoplanin Ann. Pharmacother., May 1, 2007; 41(5): 891 - 894. [Abstract] [Full Text] [PDF]